Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates
Aiko Nagayama, Neelima Vidula, Aditya Bardia
ONCOLOGY (2021), Iss. 3505, pp. 249-254
Open Access | Times Cited: 22

Showing 22 citing articles:

Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 115
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 495-498
Closed Access | Times Cited: 82
Targeting triple negative breast cancer stem cells using nanocarriers
Nagasen Dasari, Girijasankar Guntuku, Sai Kiran S. S. Pindiprolu
Discover Nano (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 17
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 557-565
Closed Access | Times Cited: 80
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic
Ana Isabel Fraguas‐Sánchez, Irene Lozza, Ana Isabel Torres‐Suárez
Cancers (2022) Vol. 14, Iss. 5, pp. 1198-1198
Open Access | Times Cited: 54
Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
Arutha Kulasinghe, James Monkman, Esha T. Shah, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 35
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Update on triple‐negative breast cancers – highlighting subtyping update and treatment implication
Julia Y. Tsang, Gary M. Tse
Histopathology (2022) Vol. 82, Iss. 1, pp. 17-35
Closed Access | Times Cited: 26
Ceritinib is a novel triple negative breast cancer therapeutic agent
Shengli Dong, Hassan Yousefi, Isabella Van Savage, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 21
PD-L1 intrinsically promotes the proliferation of breast cancer cells through the SKP2-p27/p21 axis
Marwa Elfoly, Jumanah Y. Mirza, Ayodele Alaiya, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in PreclinicalIn VivoModels
Ulrich H. Weidle, Fabian Birzele
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 2, pp. 117-131
Open Access | Times Cited: 10
Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review
Josephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 3
Humanized dual-targeting antibody–drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity
Ming‐Hai Wang, Qi Ma, Sreedhar Reddy Suthe, et al.
Acta Pharmacologica Sinica (2025)
Open Access
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Mehrnoosh Pauls, Stephen Chia, Nathalie LeVasseur
Current Oncology (2022) Vol. 29, Iss. 7, pp. 4748-4767
Open Access | Times Cited: 15
Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer
Wenxing Qin, Jia Li, Na Gao, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer
Young Seok Cho, Ha Rin Kim, Seong Jin Park, et al.
Biomaterials (2022) Vol. 289, pp. 121783-121783
Open Access | Times Cited: 13
Exogenous hydrogen sulfide (H2S) exerts therapeutic potential in triple-negative breast cancer by affecting cell cycle and DNA replication pathway
Xiaoyue Cui, Rui Liu, Lian Duan, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114488-114488
Open Access | Times Cited: 6
PPAB001, a novel bispecific antibody against CD47 and CD24, enhances anti-PD-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype
Yun Yang, Jianqin Li, Jing Zhang, et al.
International Immunopharmacology (2024) Vol. 144, pp. 113740-113740
Closed Access | Times Cited: 1
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
Novel Thienopyrimidine-Hydrazinyl Compounds Induce DRP1-Mediated Non-Apoptotic Cell Death in Triple-Negative Breast Cancer Cells
Saloni Malla, Angelique Nyinawabera, Rabin Neupane, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2621-2621
Open Access
Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis
John Leung, Yun-Sheng Tai, Shyh-Yau Wang, et al.
Expert Opinion on Drug Safety (2022) Vol. 22, Iss. 3, pp. 243-252
Closed Access | Times Cited: 2
Updates in the Management of Triple Negative BC: Review article
Eman Ibrahim Abdelshakour, Emad Eldin Hassan, Elsayed Mostafa Ali
The Egyptian Journal of Hospital Medicine (2023) Vol. 92, Iss. 1, pp. 5687-5691
Open Access
Page 1

Scroll to top